# Pizarra — PT-pseudo_2cd88bcdf81c (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2cd88bcdf81c
Task: 1

Encounter: Urology - outpatient on 02 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 73-year-old male
  - PSA: 12.0 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.313 ng/mL²
  - PSA velocity: 2.57 ng/mL/yr
  - Prior PSA: 12.1 ng/mL
  - Prostate volume: 38.29 mL
  - Months since last PSA: 1
  - DRE findings: Not done (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8336016 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 12 ng/mL. PI-RADS 4. PSAD 0.31. Prostate volume 38 mL. csPCa 0.83.

Vitals: weight 74 kg, height 189 cm, BMI 20.7, BP 116/67 mmHg, HR 76 bpm. Smoking: Current smoker (25 pack-yr).

Chief complaint: Persistent elevation of prostate-specific antigen levels alongside a previously negative biopsy necessitates clinical reassessment.

History: Most recent prostate-specific antigen measurement stands at 12.0 ng/mL, recorded in January 2025. At seventy-three years of age, this divorced retired carpenter resides independently while sustaining an active routine that includes biweekly tennis matches. A substantial smoking history of 25 pack-yr remains current. Lower urinary tract symptoms are negligible, scoring merely 2 on the IPSS scale, with complete denial of hematuria or pelvic discomfort. Weekly alcohol intake averages twenty-six units, and recent visits covered standard dental care alongside endocrine screening for thyroid surveillance. Invasive interventions provoke marked anxiety, prompting a request for detailed explanations and extended consultation periods. Past medical background remains clear of comorbidities, with no prescribed medications and zero documented allergies.

Physical examination: DRE — texture: N/A, mobility: N/A, asymmetry: N/A. The examination was omitted entirely because of scheduling limitations and the patient’s explicit preference. General assessment shows stable parameters: blood pressure sits at 116/67 mmHg, heart rate rests at 76 bpm, and body mass index measures 20.7. Palpation of the abdomen yields a soft, non-tender response without detectable masses or organ enlargement.

Patient info: retired carpenter; Divorced; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 26 units / week; exercise Tennis 2x/week; IPSS score: 2/35 (mild LUTS).

Recent other appointments: Endocrine — thyroid screening; Dental — biannual check-up.
Admin: Patient anxious about procedures — allocate extra consult time.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.83 +/- 0.07   (95% CI 0.69-0.97)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.07  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.65 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: dre_ord.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior negative biopsy.

CRITERION VERDICT: BIOPSY.

The criterion: Re-biopsy (targeted) when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for a PI-RADS 3 or lower picture that has not changed.

In the labelled cohort this criterion matched the reading urologist in 16 of the 18 cases with a prior negative biopsy.

Track record of this criterion on the labelled cohort: 16 of 18 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
  - psa_trend (get_psa_trend) -> Does the PSA trend provide evidence that contradicts the prior negative biopsy status?
  - previous_notes (get_previous_notes) -> What was the prior management context, including prior grade and surveillance pathway?

This case hinges on whether the PI-RADS score from the MRI, the PSA trend, the prior management context, or specific laboratory findings override the statistical prior and the guideline criterion suggesting a biopsy. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the structured panel, failing to weigh the patient's high PSA velocity (2.57 ng/mL/yr) and the high csPCa predicted probability (0.8336016). It also did not incorporate the specific PI-RADS score of 4, which is a key factor in the guideline criterion.

WHY THE SUGGESTION COULD BE WRONG
The prior suggests biopsy based on a high probability, but the guideline criterion is conditional on the MRI finding (PI-RADS 4-5 lesion). If the MRI report shows a PI-RADS 3 or lower picture that has not changed, the protocol suggests against repeating a negative biopsy. The prior's high probability might be driven by the PSA/volume/prior negative status, which the protocol explicitly states should be overridden by the MRI finding.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 4-5 lesion that warrants re-biopsy?
psa_trend - Does the PSA trend provide evidence that contradicts the prior negative biopsy status?
previous_notes - What was the prior management context, including prior grade and surveillance pathway?
previous_notes - What was the prior management context, including prior grade and surveillance pathway?
previous_notes - What was the prior management context, including prior grade and surveillance pathway?
GUIDELINE ANCHOR
The guideline states that a repeat biopsy is mandated when the mpMRI shows a PI-RADS 4-5 lesion, and stable MRI (PI-RADS 1-3) does not make repeat biopsy superfluous.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: Focal lesion in the right mid-prostate peripheral zone with imaging features highly suspicious for malignancy. PI-RADS 4. Lesion size is 14 x 11 mm. No comparison with a previous MRI was explicitly detailed in the prose, but the finding is described as a focal lesion.
get_psa_trend
PSA trend: PSA increased from 2.3 ng/mL in Dec 2022 to 5.3 ng/mL in Dec 2023, and further to 12.0 ng/mL in Jan 2025.
get_previous_notes
Previous notes: On 07 May 2024, a transrectal ultrasound-guided biopsy was performed, yielding a negative result for malignancy.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not require them, and the retrieved documents did not raise any specific questions requiring this panel.

WHAT THE EVIDENCE SUPPORTS
FOR Sampling this patient now:
- MRI report: PI-RADS 4 lesion (14 x 11 mm) highly suspicious for malignancy.
- PSA trend: Significant rising trend, with a jump from 5.3 ng/mL to 12.0 ng/mL over approximately 1 year.
- Guideline Criterion: The criterion mandates re-biopsy for a PI-RADS 4-5 lesion.

AGAINST Sampling this patient now:
- Previous notes: Prior biopsy was negative.

WHERE THIS LEANS
The evidence strongly supports sampling due to the PI-RADS 4 finding on the MRI and the rising PSA trend, which aligns with the guideline criterion for re-biopsy.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (PI-RADS 4 lesion and rising PSA trend) strongly supports the guideline criterion for re-biopsy, leading to a clear recommendation.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to recommend biopsy is clear because the retrieved evidence strongly aligns with both the guideline criterion and the statistical prior. The PI-RADS 4 finding on the mpMRI, coupled with the rising PSA trend from 5.3 ng/mL to 12.0 ng/mL, mandates re-biopsy according to protocol. This finding overturned any potential hesitation based on the prior negative biopsy status.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
